AAAAAA

   
Results: 1-8 |
Results: 8
COMBINED LEVAMISOLE WITH RECOMBINANT INTERLEUKIN-2 (IL-2) IN PATIENTSWITH ADVANCED RENAL-CELL CARCINOMA - A PHASE-II STUDY
Authors: CREAGAN ET HESTORRF RD SUMAN VJ MAILLIARD JA NAIR S KROOK JE KUGLER JW MARSCHKE RF MICHALAK JC TSCHETTER LK
Citation: Et. Creagan et al., COMBINED LEVAMISOLE WITH RECOMBINANT INTERLEUKIN-2 (IL-2) IN PATIENTSWITH ADVANCED RENAL-CELL CARCINOMA - A PHASE-II STUDY, American journal of clinical oncology, 21(2), 1998, pp. 139-141
THE POSSIBLE ADVANTAGE OF HYPERFRACTIONATED THORACIC RADIOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED NONSMALL CELL LUNG-CARCINOMA - RESULTS OF A NORTH CENTRAL CANCER-TREATMENT GROUP PHASE-III STUDY
Authors: BONNER JA MCGINNIS WL STELLA PJ MARSCHKE RF SLOAN JA SHAW EG MAILLIARD JA CREAGAN ET AHUJA RK JOHNSON PA
Citation: Ja. Bonner et al., THE POSSIBLE ADVANTAGE OF HYPERFRACTIONATED THORACIC RADIOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED NONSMALL CELL LUNG-CARCINOMA - RESULTS OF A NORTH CENTRAL CANCER-TREATMENT GROUP PHASE-III STUDY, Cancer, 82(6), 1998, pp. 1037-1048
PHASE-II STUDY OF COMBINED LEVAMISOLE WITH RECOMBINANT INTERLEUKIN-2 IN PATIENTS WITH ADVANCED MALIGNANT-MELANOMA
Authors: CREAGAN ET ROWLAND KM SUMAN VJ KARDINAL CG MARSCHKE RF MARKS RS MAPLES WJ
Citation: Et. Creagan et al., PHASE-II STUDY OF COMBINED LEVAMISOLE WITH RECOMBINANT INTERLEUKIN-2 IN PATIENTS WITH ADVANCED MALIGNANT-MELANOMA, American journal of clinical oncology, 20(5), 1997, pp. 490-492
EVALUATION OF INTRAVENOUS 6-THIOGUANINE AS FIRST-LINE CHEMOTHERAPY INWOMEN WITH METASTATIC BREAST-CANCER
Authors: INGLE JN TWITO DI SUMAN VJ KROOK JE MAILLIARD JA WINDSCHITL HE MARSCHKE RF
Citation: Jn. Ingle et al., EVALUATION OF INTRAVENOUS 6-THIOGUANINE AS FIRST-LINE CHEMOTHERAPY INWOMEN WITH METASTATIC BREAST-CANCER, American journal of clinical oncology, 20(1), 1997, pp. 69-72
NEUROENDOCRINE DIFFERENTIATION IS AN INDEPENDENT PROGNOSTIC FACTOR INCHEMOTHERAPY-TREATED NONSMALL CELL LUNG-CARCINOMA
Authors: SCHLEUSENER JT TAZELAAR HD JUNG SH CHA SS CERA PJ MYERS JL CREAGAN ET GOLDBERG RM MARSCHKE RF
Citation: Jt. Schleusener et al., NEUROENDOCRINE DIFFERENTIATION IS AN INDEPENDENT PROGNOSTIC FACTOR INCHEMOTHERAPY-TREATED NONSMALL CELL LUNG-CARCINOMA, Cancer, 77(7), 1996, pp. 1284-1291
EVALUATION OF A SOMATOSTATIN ANALOG IN THE TREATMENT OF LYMPHOPROLIFERATIVE DISORDERS - RESULTS OF A PHASE-II NORTH CENTRAL CANCER-TREATMENT GROUP TRIAL
Authors: WITZIG TE LETENDRE L GERSTNER J SCHROEDER G MAILLIARD JA COLONOTERO G MARSCHKE RF WINDSCHITL HE
Citation: Te. Witzig et al., EVALUATION OF A SOMATOSTATIN ANALOG IN THE TREATMENT OF LYMPHOPROLIFERATIVE DISORDERS - RESULTS OF A PHASE-II NORTH CENTRAL CANCER-TREATMENT GROUP TRIAL, Journal of clinical oncology, 13(8), 1995, pp. 2012-2015
ADVANCED COLORECTAL ADENOCARCINOMA - TREATMENT WITH AMONAFIDE
Authors: MARSCHKE RF WIEAND HS OCONNELL MJ SCHUTT AJ BURCH PA KOVACH JS
Citation: Rf. Marschke et al., ADVANCED COLORECTAL ADENOCARCINOMA - TREATMENT WITH AMONAFIDE, Journal of the National Cancer Institute, 86(12), 1994, pp. 944-945
PROSPECTIVE PHASE-I EVALUATION OF RADIATION-THERAPY, 5-FLUOROURACIL, AND LEVAMISOLE IN LOCALLY ADVANCED GASTROINTESTINAL CANCER
Authors: MARTENSON JA SCHUTT AJ GRADO GL MAPLES WJ MARSCHKE RF
Citation: Ja. Martenson et al., PROSPECTIVE PHASE-I EVALUATION OF RADIATION-THERAPY, 5-FLUOROURACIL, AND LEVAMISOLE IN LOCALLY ADVANCED GASTROINTESTINAL CANCER, International journal of radiation oncology, biology, physics, 28(2), 1994, pp. 439-443
Risultati: 1-8 |